Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
shape increases » showed increases (Expand Search), sharp increase (Expand Search), disease increases (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
shape increases » showed increases (Expand Search), sharp increase (Expand Search), disease increases (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
-
2201
-
2202
-
2203
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2204
-
2205
-
2206
-
2207
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2208
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2209
-
2210
-
2211
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2212
-
2213
-
2214
-
2215
-
2216
-
2217
-
2218
-
2219
-
2220
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: